Breast cancer is the most common malignant cancer in women. CYP24A1 expression regulates cellular response to vitamin D, which has antitumor effects against breast cancer. This study aimed to identify the correlation between CYP24A1 mRNA expression and prognosis of breast cancer. This study enrolled 1102 patients, including 1090 females and 12 males, from TCGA-BRCA cohort. The Cancer Genome Atlas database was used to study CYP24A1 mRNA expression in breast cancer, and Chi-squared tests were performed to test the correlation between clinical features and CYP24A1 expression. The prognostic value of CYP24A1 in breast cancer was assessed using Kaplan-Meier curves and Cox analysis. Low CYP24A1 expression was associated with age, molecular subtype, ER, PR, HER2, menopause status, N classification, vital status, overall survial and relapse-free survival. CYP24A1 presented a moderate diagnostic ability in breast cancer. Furthermore, low CYP24A1 expression was correlated with poor prognosis. CYP24A1 was an independent risk factor for breast cancer. CYP24A1 plays an important role in prognosis of breast cancer. CYP24A1 has the potential to be a biomarker, especially in predicting prognosis.
Continued survival is 1261.6 days and 1262.8 days respectively, and the number of events was 154. The detailed clinical characteristics of these corresponding patients are shown in Table 1 , including molecular subtype, TNM stage, survival status and radiation therapy. vital status. Patients who were less than 60 years old had higher CYP24A1 expression levels than patients who were more than 60 years old ( Fig. 1B ). Female patients had higher CYP24A1 expression levels than male patients (Fig. 1C , p = 0.039), but further studies need to be performed due to the limited number of male patients. With regard to the molecular subtype, only basal breast cancer had higher CYP24A1 expression compared to normal tissue, while Lum A, HER2 and Lum B had lower CYP24A1 expression compared to normal tissue ( Fig. 1D ). Positive ER, PR and HER2 groups had lower CYP24A1 expression than negative groups ( Fig. 1E -G). As shown in Fig. 1H , indemenopausal, perimenopausal and premenopausal groups had similar CYP24A1 expression, while the postmenopausal group had lower CYP24A1 expression compared to the other groups. CYP24A1 mRNA expression levels of different T and N classifications are shown in Fig. 1I ,J. Breast cancer with a positive lymph node status had higher CYP24A1 expression than breast cancer with a negative lymph node status ( Fig. 1K ). Although the p value was greater than 0.05, the group with close margin status had higher expression than the negative and positive groups ( Fig. 1L ). Deceased patients with breast cancer had lower CYP24A1 expression than living patients with breast cancer (Fig. 1M ).
Capability of CYP24A1 to diagnose breast cancer. We used the receiver-operating characteristic (ROC) curve of CYP24A1 to analyze the diagnostic capability of CYP24A1. As shown in Fig. 2 , a moderate diagnostic ability in breast cancer was observed with the area under the curve (AUC) of 0.678. We also analyzed the diagnostic capability of CYP24A1 in different stages, and similar results were found with AUC values of 0.651 (stage 1), 0.670 (stage 2), 0.703 (stage 3) and 0.760 (stage 4), showing a progressive increase with higher stages.
Relationships between clinical characteristics and CYP24A1 expression.
We divided the results into two groups based on the medium value for analysis of the relationship between clinical features and CYP24A1 mRNA expression ( Table 2) . The threshold CYP24A1 level identified from the ROC curve was used to form the low-and high-groups. According to Chi-square tests, low CYP24A1 mRNA expression was highly associated with age, molecular subtype, ER, PR, HER2, menopause status, N classification, vital status, overall survial and relapse-free survival (with P value < 0.01). Moreover, gender (P = 0.0175), histological type (P = 0.034) and neoadjuvant treatment (P = 0.045) were correlated with CYP24A1 expression.
CYP24A1 mRNA expression is correlated with overall survival. As shown in Fig. 3 , the Kaplan-Meier survival curve with the log rank test revealed the relationship between CYP24A1 mRNA expression and overall survival of patients. Low CYP24A1 expression was significantly associated with poor overall survival (P < 0.0001). The subgroup analysis showed that low CYP24A1 expression indicated a poor overall survival of patients with basal (P = 0.0049), HER2 (P = 0.044), Lum A (P = 0.11) and Lum B (P = 0.013) breast cancer. Additionally, poor overall survival was associated with HER2-negative tumors, HER2-positive tumors, ER-negative tumors, ER-positive tumors, PR-negative tumors, PR-positive tumors, infiltrating ductal carcinoma and infiltrating lobular carcinoma. Univariate Cox analysis identified critical variables, including age, HER2, CYP24A1 mRNA expression is associated with relapse-free survival. The Kaplan-Meier survival curve was used for evaluating the relationship between CYP24A1 expression and relapse-free survival (Fig. 4 ). Similar to the consequences above, low CYP24A1 expression showed a close association with basal tumors, Lum A tumors, Lum B tumors, ER-negative tumors, ER-positive tumors, PR-negative tumors, PR-positive tumors, infiltrating ductal carcinoma and infiltrating lobular carcinoma. Low CYP24A1 expression presented remarkable prognostic value (P < 0.0001). Moreover, univariate Cox analysis was used to select the key prognostic factors (ER, PR, stage, margin status, and CYP24A1), and multivariable analysis was used to adjust the interaction between factors. Furthermore, given that proliferation is a strong prognostic component in ER-positive breast cancer, the correlation between CYP24A1 expression and KI67 (gene MKI67) has been studied. The result showed they are strongly correlated (R 2 = 0.00219, Fig. S1 ). CYP24A1 expression was an independent prognostic factor for patients with breast cancer as confirmed by univariate and multivariate Cox analyses ( Table 4 , with 912 patients actually included in the multivariable Cox analyses).
Discussion
Our group has recently been studying biomarkers for prognosis of cancers [12] [13] [14] [15] [16] [17] [18] . The present study focused on CYP24A1 mRNA expression and demonstrated the important role of CYP24A1 in breast cancer. Low CYP24A1 expression was associated with age, ER, menopause status, TNM classification, stage, margin status, vital status and radiation therapy. In addition, CYP24A1 expression was an independent prognostic factor of breast cancer, making it a promising biomarker with great potential in the near future. However, in contrast with a previously finding that high CYP24A1 expression is upregulated in tumorous breast tissue 6 , we presented a newfound correlation between low expression of CYP24A1 and poor prognosis. The difference may be due to the different ethnicities of people as the tumor samples in the previously reported experiments were collected from the Imam Khomeini Hospital in Iran 6 . Moreover, the sample sizes may have also contributed to the difference (30 vs. 1102 in our study). Although one experiment has suggested that high CYP24A1 expression promotes breast cancer growth 7 , we believe our results and take in vivo and in vitro discrepancies into consideration. Analysis of malignant and benign breast tumors obtained from patients after surgery has demonstrated CYP24A1 splicing in breast cancer, and the expression of CYP24A1 protein is significantly reduced in cancerous tissue compared to benign tissue 19 . Our result was consistent with this finding and may be attributed to CYP24A1 splicing because different splicing variants would lead to dysfunction of enzymes, in which enzymes only bind substrates but lack catalytic ability, therefore resulting in abnormal vitamin D levels 19, 20 . Low CYP24A1 expression indicates that less CYP24A1 enzyme is produced, leading to more active vitamin D. As two previous studies have disagreed with Yao et al., who reported that serum level of vitamin D is associated with lower risk of breast cancer morbidity and mortality, it remains disputable whether vitamin D is good or bad for breast cancer survival 21, 22 . The expression of vitamin D receptor was diminished in malignant breast cancer and shown to correlate with a longer relapse-free survival 23, 24 . Active vitamin D form (1,25D3) could induce the expression of CYP24A1 through functional vitamin D receptor 25 . However, breast cancer cells may reduce the expression of vitamin D receptor to resist the anti-proliferative effects by vitamin D receptor-mediated vitamin D control 23 . With fewer vitamin D receptors, the inducible expression of CYP24A1 could be limited as well. Survivin suppresses vitamin D, which inhibits cancer cell proliferation, indicating that survivin is an important molecule for the viability of myocytes. Vitamin D inhibits the growth of breast cancer cells. However, considering that breast cancer patients have increased risk for cardiovascular diseases, vitamin D may adversely affect outcomes during the acute phase of cardiovascular conditions, further leading to death caused by noncancer 21 . Because noncancer causes of death are higher than cancer causes of death in breast cancer 26 , we not only focused on the inhibition effect of vitamin D on breast cancer cells but also considered the influence of vitamin D on cardiovascular and other systems as it is a dilemma to obtain a conclusion that high level of vitamin D benefits patients with breast cancer. This point of view was further supported by a newly published article in The New England Journal of Medicine (Manson et al.) , which demonstrated that supplementation with vitamin D does not result in a lower incidence of invasive cancer or cardiovascular events compared to placebo 27 with a hazard ratio of 1.02 and 95% CI of 0.79 to 1.31 www.nature.com/scientificreports www.nature.com/scientificreports/ for breast cancer, indicating no significant difference. Our results were similar to those of that clinical trial as increases in serum vitamin D by intrinsic regulation or extrinsic supplementation may not lower the risk but may be associated with poor prognosis. Similar to results found in other cancers, including lung adenocarcinoma and colorectal cancer 10, 11, 28 , CYP24A1 may be a promising biomarker in breast cancer. Nevertheless, a consensus has not been reached yet on whether upregulation or downregulation of CYP24A1 leads to poor prognosis when considering the inconclusive function of high vitamin D. Many studies investigated the prognostic role of KI67 in breast cancer and found an increasing value with more evidence 29 . In prognosis, a KI67 level above 10-14% has been suggested to define a group with high risk 29 . Proliferation is a strong prognostic component in ER-positive breast cancer and the strong correlation between CYP24A1 expression and KI67 could possibly further suggest the prognostic value of CYP24A1.
To the best of our knowledge, this is the first study to investigate the correlation between CYP24A1 mRNA expression and prognosis of breast cancer using meta-analysis on a relatively extensive scale. The present study sheds light on the important role of CYP24A1 in breast cancer. However, based on the complexity of the role of vitamin D in breast cancer, the specific function of CYP24A1 needs to be further elucidated by clinical trials in the future. 
Materials and Methods
Data collection from TCGA database. The RNA expression data was downloaded from the Cancer Genome Atlas (https://cancergenome.nih.gov/) and was shown in RSEM normalized count transformed through calculation using log2(x + 1). The clinicopathological details and related information of breast cancer patients were also collected. This study enrolled 1102 patients, including 1090 females and 12 males, with 589 patients Table 3 . Summary of univariate and multivariate Cox regression analyses of overall survival duration. 
